Supplementary Figures 1 through 8 from 177Lu-EC0800 Combined with the Antifolate Pemetrexed: Preclinical Pilot Study of Folate Receptor Targeted Radionuclide Tumor Therapy

Le résumé fourni par la source

PDF - 569KB, Figure S1: Chemical structures of the compounds applied in this study. Figure S2: Results of the internalization studies of 177Lu-EC0800 performed with FR-positive and FR-negative tumor cell lines Figure S3: Results of a clonogenic assay performed with 177Lu-EC0800 with/without co-application of folic acid using KB and IGROV-1 tumor cells Figure S4: Representation of the area under the curve (AUC) necessary to determine the absorbed dose to the tumors and kidneys. Figure S5: Results of the biodistribution data obtained in KB tumor bearing nude mice injected with 3H-pemetrexed Figure S6: Graphs representing the body weight and survival of mice treated with pemetrexed compared to untreated control mice. Figure S7: Distribution of the cell fractions in a particular cell cycle phase after treatment with 177Lu-EC0800, PMX or both of these agents. Figure S8: Graphs representing the apoptotic fraction of KB and IGROV-1 cells after treatment with 177Lu-EC0800, PMX or both of these agents.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.